Abstract
PURPOSE: Human monoclonal antibody (HuMAb) SK1, a human monoclonal IgM, has previously been shown to react selectively with a wide range of human carcinomas. In this study, the complement-dependent cytotoxicity (CDC) mediated by the HuMAb SK1 was investigated. METHODS: The presence of AgSK1 on the two studied cell lines, HT29 and PANC-1, was evaluated by the immunocytochemical staining. The intracellular and surface locations of the targeting antigen of HuMAb SK1 were further characterized by the study of flow cytometry. The specific lysis of target cells by the HuMAb SK1 in the CDC assay was studied. RESULTS: In the presence of human complement, the HuMAb SK1 was shown to be effective in the lysis of cultured human gastrointestinal cancer cells as well as the fresh colon cancer cells derived from the patient's specimens. In addition, our data suggested that HuMAb SK1 activated the mouse complement in a similar magnitude. CONCLUSIONS: We concluded that HuMAb SK1 showed some promise for future clinical trials. The in vitro CDC effect of HuMAb SK1 with mouse complement suggested that the antitumor effect of HuMAb SK1 might be successfully studied in the nude mouse model bearing xenografts of human colon cancer as a part of the preclinical evaluation.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Koda K, Glassy MC, Chang HR. Generation of human monoclonal antibodies against colon cancer. Arch Surg 1990;125:1591–7.
Chang HR, Koda K, McKnight M, Glassy MC. Tumor associated antigens recognized by human monoclonal antibodies. Ann Surg Oncol (in press).
Chang HR, Koda K, Chang S, Baird S. AgSK1, a novel carcinoma associated antigen. Cancer Res 1993; 53:1122–7.
Irie RF, Morton D. Regression of cutaneous metastatic melanoma by intralesional injection with human monoclonal antibody to ganglioside GD2. Proc Natl Acad Sci USA 1986;83:8694–8.
Ziegler EJ, Fisher CJ, Sprung CL,et al. Treatment of gram-negative bacteremia and septic shock with HA1A human monoclonal antibody against endotoxin. N Engl J Med 1991;324:429–36.
Houghton AN, Mintzer D, Cardon-Cardo C,et al. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 1985;82:1242–6.
Cheung N-K, Lazarus H, Miraldi FD,et al. Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol 1987;5:1430–40.
Primus FG, Pendurthi TK, Hutzell P,et al. Chimeric B 72.3 mouse human (γ1) antibody directs the lysis of tumor cells by lymphokine activated killer cells. Cancer Immunol Immunother 1990;31:349–57.
Saarinen UM, Coccia PF, Gerson SL, Pelley R, Cheung N-K. Eradication of neuroblastoma cellsin vitro by monoclonal antibody and human complement: Method for purging autologous bone marrow. Cancer Res 1985;45:5969–75.
Capone PM, Pasidero LD, Croghan GA, Chu TM. Experimental tumoricidal effects of monoclonal antibody against solid breast tumors. Proc Natl Acad Sci USA 1983;80:7328–32.
Author information
Authors and Affiliations
Additional information
This study was supported in part by Grant R29 CA56299-01A1 from the National Cancer Institute.
About this article
Cite this article
Chang, H.R., Chavoshan, B. & Park, H. Human monoclonal antibody SK1-mediated cytotoxicity against colon cancer cells. Dis Colon Rectum 36, 1152–1157 (1993). https://doi.org/10.1007/BF02052265
Issue Date:
DOI: https://doi.org/10.1007/BF02052265